公开(公告)号：US12042560B2

公开(公告)日：2024-07-23

申请号：US14061426

申请日：2013-10-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Hiroshi Kikuchi ,  Kenji Hyodo ,  Hiroshi Ishihara

IPC: A61K9/127 ,  A61K31/357

CPC classification number: A61K9/127 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/1278 ,  A61K31/357

Abstract: The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.

公开(公告)号：US11998544B2

公开(公告)日：2024-06-04

申请号：US17059876

申请日：2019-05-31

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ermira Pazolli ,  Silvia Buonamici ,  James Palacino ,  Michael Seiler ,  Ping Zhu ,  Evan Barry ,  Lihua Yu

IPC: A61K31/496 ,  A61K35/17 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K47/68

CPC classification number: A61K31/496 ,  A61K35/17 ,  A61K38/191 ,  A61K38/2013 ,  A61K38/2066 ,  A61K38/208 ,  A61K38/2086 ,  A61K38/217 ,  A61K39/0011 ,  A61K39/39 ,  A61K39/3955 ,  A61K47/6803 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6056 ,  A61K2039/6081

Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

公开(公告)号：US11926619B2

公开(公告)日：2024-03-12

申请号：US17045952

申请日：2019-04-08

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Gregg F. Keaney ,  John Wang ,  Baudouin Gerard ,  Kenzo Arai ,  Xiang Liu ,  Guo Zhu Zheng ,  Kazunobu Kira ,  Lisa A. Marcaurelle ,  Marta Nevalainen ,  Ming-Hong Hao ,  Morgan Welzel O'Shea ,  Parcharee Tivitmahaisoon ,  Sudeep Prajapati ,  Tuoping Luo ,  Nicholas C. Gearhart ,  Jason T. Lowe ,  Yoshihiko Kotake ,  Satoshi Nagao ,  Regina Mikie Kanada Sonobe ,  Masayuki Miyano ,  Norio Murai ,  Andrew Cook ,  Shelby Ellery ,  Atsushi Endo ,  James Palacino ,  Dominic Reynolds

IPC: C07D407/12 ,  A61K31/365 ,  A61K31/4427 ,  A61K31/497 ,  A61K45/06 ,  A61P35/00 ,  C07D313/00 ,  C07D405/12 ,  C07D405/14 ,  C07D407/06 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107

CPC classification number: C07D407/06 ,  A61K45/06 ,  A61P35/00 ,  C07D313/00 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

公开(公告)号：US11833119B2

公开(公告)日：2023-12-05

申请号：US16961292

申请日：2019-01-09

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Anand Selvaraj ,  Peter Smith

IPC: A61K31/496 ,  A61P35/00 ,  A61K31/4375

CPC classification number: A61K31/496 ,  A61K31/4375 ,  A61P35/00

Abstract: Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.

公开(公告)号：US20230338522A1

公开(公告)日：2023-10-26

申请号：US18028039

申请日：2021-10-28

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Yosuke WATANABE

IPC: A61K39/395 ,  A61K47/18 ,  A61K47/22 ,  A61K47/02 ,  A61K47/26 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61K47/183 ,  A61K47/22 ,  A61K47/02 ,  A61K47/26 ,  C07K16/28

Abstract: [Problem] The purpose of the present disclosure is to provide a highly concentrated preparation of an anti-fractalkine (FKN) antibody, the preparation having viscosity that facilitates handling. [Solution] Provided is a pharmaceutical composition containing anti-FKN antibody at a concentration of 200 mg/mL. This pharmaceutical composition is characterized by containing 200 mg/mL of anti-FKN antibody and 100 to 400 mM of a basic amino acid wherein the basic amino acid comprises at least one amino acid selected from arginine, histidine, lysine, and ornithine.

公开(公告)号：US11761045B2

公开(公告)日：2023-09-19

申请号：US17098940

申请日：2020-11-16

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Lihua Yu ,  Kian Huat Lim ,  Jacob D. Feala ,  Silvia Buonamici ,  Yoshiharu Mizui ,  Peter G. Smith ,  Ping Zhu ,  Eunice Sun Park ,  Michael W. Seiler ,  Marco Peter Fekkes

IPC: C12Q1/6886 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/55 ,  C12Q1/02 ,  C12Q1/6806 ,  C12Q1/6841

CPC classification number: C12Q1/6886 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/55 ,  A61P35/00 ,  C12Q1/025 ,  C12Q1/6806 ,  C12Q1/6841 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.

公开(公告)号：US11707448B2

公开(公告)日：2023-07-25

申请号：US17528510

申请日：2021-11-17

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Xingfeng Bao ,  Diana Albu ,  Mary Woodall-Jappe

IPC: A61K31/415 ,  A61K31/7068 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K31/415 ,  A61K31/7068 ,  A61K39/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2300/00

Abstract: The present invention provides methods and compositions for treating cancer by administering an EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy.

公开(公告)号：US20230183328A1

公开(公告)日：2023-06-15

申请号：US17906660

申请日：2021-03-19

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Nobuo YOSHIDA ,  Naomi SAKURAMOTO ,  Takahisa SAKAGUCHI ,  Hirokazu KITO ,  Takahiro OZAWA ,  Anjali JOSHI ,  Yung Yueh HSU ,  Pierre SOUILLAC

IPC: C07K16/18 ,  A61K31/133 ,  A61P25/28

CPC classification number: C07K16/18 ,  A61K31/133 ,  A61P25/28

Abstract: Provided herein are aqueous pharmaceutical formulations comprising high concentrations of anisolated anti-Aβ protofibril antibody or a fragment thereof that binds to human Aβ protofibrils, such as BAN2401, arginine, polysorbate 80, and a pharmaceutically acceptable buffer.

公开(公告)号：US11660275B2

公开(公告)日：2023-05-30

申请号：US16975865

申请日：2019-03-18

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Hiroyuki Higashiyama ,  Hisashi Wakita ,  Yoshimasa Ito ,  Yoshihide Osada

IPC: A61K31/18 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/506

CPC classification number: A61K31/18 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/506

Abstract: Provided is a combination agent that combines N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide with an AMPA-type glutamate receptor antagonist such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one or 2-fluoro-6-(3-fluoro-8-oxo-7-(pyridin-3-yl)-7,8-dihydro-6H-pyrano[3,2-b:5,4-b′]dipyridin-9-yl)benzonitrile, and it has potential for use as a therapeutic agent for epilepsy.

公开(公告)号：US20230151360A1

公开(公告)日：2023-05-18

申请号：US17791343

申请日：2021-01-28

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yuta SUZUKI ,  Kazuto YAMAZAKI ,  Kenji KUBARA ,  Tomohiko TAMURA ,  Daisuke KUROTAKI

IPC: C12N15/11 ,  A61K47/54 ,  C12N15/113

CPC classification number: C12N15/111 ,  A61K47/549 ,  C12N15/113 ,  C12N2310/315 ,  C12N2310/351

Abstract: Disclosed is a nucleic acid complex or a pharmaceutically acceptable salt thereof; the nucleic acid complex represented by the formula (I), wherein X is CH2 or O; Y is a sugar ligand having mannose or GalNAc; n is an integer of 1 to 8; and Z is a group comprising an oligonucleotide.